Literature DB >> 12110485

Evaluation of efficacy in terms of antibody levels and cell-mediated immunity of acellular pertussis vaccines in a murine model of respiratory infection.

Mineo Watanabe1, Eiji Komatsu, Takaaki Sato, Masaaki Nagai.   

Abstract

The efficacy of six acellular pertussis vaccines, prepared by various manufacturers in Japan, was investigated in a murine model of respiratory infection (aerosol challenge model) and a murine intracerebral (i.c.) challenge model. There was a good correlation between bacterial clearance from the lungs after aerosol challenge and the potency of vaccines as determined by i.c. challenge. The levels of antibodies against filamentous hemagglutinin were higher after immunizations with all tested vaccines than the levels of antibodies against pertussis toxin and pertactin. Spleen cells from mice immunized with each individual vaccine secreted interferon gamma (IFN-gamma) in response to stimulation by pertussis toxin, filamentous hemagglutinin and fimbriae. The production of interleukin-4 in response to each of the antigens tested was detected but was lower than that of IFN-gamma. However, antibody levels and cell-mediated immune responses were not correlated with the protective effects of the vaccines after aerosol challenge and after i.c. challenge.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12110485     DOI: 10.1111/j.1574-695X.2002.tb00594.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  4 in total

1.  Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model.

Authors:  Eiji Komatsu; Fuminori Yamaguchi; Akio Abe; Alison A Weiss; Mineo Watanabe
Journal:  Clin Vaccine Immunol       Date:  2010-03-31

2.  T-cell immune response assessment as a complement to serology and intranasal protection assays in determining the protective immunity induced by acellular pertussis vaccines in mice.

Authors:  C M Ausiello; R Lande; P Stefanelli; C Fazio; G Fedele; R Palazzo; F Urbani; P Mastrantonio
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

3.  Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.

Authors:  Hyo Jin Kwon; Seung Beom Han; Bo Ram Kim; Kyu Ri Kang; Dong Ho Huh; Gi Sub Choi; Dong Ho Ahn; Jin Han Kang
Journal:  BMC Infect Dis       Date:  2017-04-04       Impact factor: 3.090

4.  International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19-20 July 2007.

Authors:  M L Tondella; G M Carlone; N Messonnier; C P Quinn; B D Meade; D L Burns; J D Cherry; N Guiso; E L Hewlett; K M Edwards; D Xing; A Giammanco; C H Wirsing von König; L Han; L Hueston; J B Robbins; M Powell; C M Mink; J T Poolman; S W Hildreth; F Lynn; A Morris
Journal:  Vaccine       Date:  2008-12-09       Impact factor: 3.641

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.